Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 20;23(3):217. doi: 10.3892/mmr.2021.11856

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Ryu et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 3. — Anti-dyskinetic effects of β-Lapachone in L-DOPA-induced dyskinesia on day 10. (A) Total AIMs, (B) LOC and (C) ALO scores for 120 min after L-DOPA injection on day 10 in the vehicle + L-DOPA (n=11 animals) and 10 mg/kg β-Lapachone + L-DOPA (n=11 animals) groups. Cumulative ALO AIM scores for 120 min after L-DOPA treatment were subdivided into (D) axial, (E) limb and (F) orolingual subscores on day 10. *P<0.05, **P<0.01 (Student's t-test). Data are presented as the mean ± SEM. AIMs, abnormal involuntary movements; LOC, locomotive; ALO, axial-limb-orofacial; β-LAP, β-Lapachone; L-DOPA, 3,4-dihydroxyphenyl-l-alanine.